Histopathological prognostic factors, serum markers and selected molecular biological factors in ovarian cancer;Histopatologické prognostické faktory, sérové markery a vybrané molekulárně biologické faktory u ovariálního karcinomu

Ceska Gynekologie

Volumn 67, Issue 6, 2002, Pages 343-349

  Spacek J ^a   Jilek P ^a   Petera, J ^a   Tesarik Z ^a  

^a NONE

Author keywords

Grade; Histopathological prognostic factor; Ovarian cancer; Ploidy analysis

Indexed keywords

BIOLOGICAL MARKER; BRCA2 PROTEIN; CA 125 ANTIGEN; PROTEIN P53;

CANCER GRADING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; OVARY CARCINOMA; PLOIDY; PROTEIN BLOOD LEVEL; REVIEW;

EID: 0036947411     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Ansell, S. M., Rappoport, B. L., Falkson, G. et al.: Survival determinants in patients with advanced ovarian cancer. Gynecol. Oncol., 30, 1993, s. 215-220.
2. Baak, J. P., Langley, F. A., Talerman, A. et al.: Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal. Quant. Histol., 8, 1986, s. 354-357.
3. Barber, H. R. K., Sommers, S. C., Snyder, R. et al.: Histologic and nuclear grading and stromal reactions as indices for prognosis of ovarian cancer. Am. J. Obstet. Gynecol., 121, 1975, s. 795-807.
4. Bast, R. C., Klug, T. L., St John, E. et al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 309, 1983, s. 883-887.
5. Berchuck, A., Kamel, A., Whitaker, R. et al.: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer, 50, 1990, s. 4087-4091.
6. Berchuck, A., Lambers, A., Schildkraut, J. M.: Relationship between alterations in the p53 tumor supressor gene and prognosis of ovarian cancer. CME, J. Gynec. Oncol., 4, 1999, s. 215-218.
7. Bertelsen, K., Holund, B., Andersen, E.: Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int. J. Gynecol. Cancer., 3, 1993, s. 72-79.
8. Blumenfeld, D., Braly, P. S., Ben-Ezra, J. et al.: Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma. Gynecol. Oncol., 27, 1987, s. 389-398.
9. Bonte, J.: Steroid hormone receptors as possible prognostic factors in epithelial ovarian carcinoma. CME, J. Gynec. Oncol., 4, 1999, s. 178-179.
10. Burton, J. L., Wells, M.: The role of apoptosis in the prognosis of epithelial ovarian carcinoma. CME, J. Gynec. Oncol., 4, 1999, s. 238-242.
11. Chadba, S. et al.: An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum. Pathol., 24, 1993, s. 90-95.
12. Colgan, T. J., Norris, H. J.: Ovarian tumours of low potential malignancy: A review. Int. J. Gynecol. Oncol., 1, 1983, s. 367-382.
13. Crispens, M. A., Bodurka, D., Deavers, M. et al.: Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet. Gynecol., 99, 2002, s. 3-10.
14. Czernoblisky, B., Silverman, B. B., Mikuta, J. J.: Endometrial carcinoma of the ovary. A clinico-pathological study of 75 cases. Cancer., 26, 1970, s. 1141-1152.
15. Friedlander, M. L.: Prognostic Factors in Ovarian Cancer. Seminars in Oncology, 25, 1998, 305-314.
16. Friedlander, M. L., Hedley, D. H., Taylor, I. et al.: Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res., 44, 1984, s. 397-400.
17. Gershenson, D. M., Silva, E. G.: Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer, 65, 1990, s. 578-584.
18. Goff, B. A., De La Cuesta, R. S., Muntz, H. G. et al.: Clear carcinoma of the ovary. A distinct histologic type with poor prognosis and resistance to platinum based chemotherapy in stage III disease. Gynecol. Oncol., 60, 1996, s. 412-417.
19. Green, J. A., Berns, E., Hensen-Longmans, S. et al.: Biological markers in ovarian cancer - implications for clinical practice. CME, J. Gynec. Oncol., 4, 1999, s. 13-21.
20. Hernandez, E., Bhagavan, B. S., Parmley, T. H. et al.: Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol. Oncol., 17, 1984, s. 117-123.
21. Högberg, T., Carstensen, J., Simonson, E.: Treatment results and prognostic factors in a population - based study of epithelial ovarian cancer. Gynecol. Oncol., 48, 1993, s. 38-49.
22. Hopkins, M. P., Kumar, N. B., Morley, G. W.: An assessment of pathologic features and treatment modalities in ovarian tumors of low malignant potential. Obstet. Gynecol., 70, 1987, s. 923-929.
23. Ingelman-Sandberg, A.: Classification and staging of malignant tumours of the female pelvis. Acta Obstet. Gynecol. Scan., 50, 1971, s. 1-7.
24. Kacinski, B. M., Mayer, A. G., King, B. L. et al.: Neu protein overexpressionin benign, borderline, and malignant ovarian neoplasms. Gynecol. Oncol., 44, 1992, s. 245.
25. Kaern, J., Trope, C. G., Kristensen, G. B. et al.: DNA ploidy: The most important prognostic factor in patients with borderline tumors of the ovary. Int. J. Gynecol. Cancer, 33, 1993, s. 49-358.
26. Kallioniemi, O. P., Punnonen, R., Mattila, J. et al.: Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian cancer. Cancer, 61, 1988, s. 334-339.
27. Kennedy, A. W., Hart, W. R.: Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). Cancer, 78, 1996, s. 278-286.
28. Kerr, J. F. R., Winterford, C. m., Harmon, B. V.: Apoptosis: its significance in cancer and cancer therapy. Cancer, 73, 1994, s. 2013-2026.
29. Klemi, P. J., Pylkkanen, L., Kiilholma, P. et al.: P53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian cancer. Cancer, 76, 1995, s. 1201-1208.
30. Kohler, M. F., Marks, J. R., Wiseman, R. W. et al.: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst., 85, 1993, s. 1513-1519.
31. Leake, J. F., Currie, J. L., Rosenheim, N. B. et al.: Long term follow up of serous ovarian tumors of low malignant potential. Gynecol. Oncol., 47, 1992, s. 150-158.
32. Leary, J. A., Edwards, B. G., Houghton, C. R. S. et al.: Amplification of HER-2/neu oncogene in human ovarian cancer. Int. J. Gynecol. Cancer, 2, 1992, s. 291-294.
33. Levesque, M. A., Katsaros, D., Yu, H. et al.: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer, 75, 1995, s. 1327-1338.
34. Levine, A. J., Momad, J., Finlay, C. A.: The p53 tumour suppressor gene. Nature, 351, 1991, s. 453-456.
35. Lund, B., Thomsen, H. K., Olsen, J.: Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clin. Implications APMIS, 99, 1991, s. 353-358.
36. Malkasian, G. D., Decker, D. G., Webb, M. J.: Histology of epithelial tumours of the ovary: Clinical usefulness and prognostic significance of histologic classification and grading. Semin. Oncol., 2, 1975, s. 191-201.
37. Marcus, J. N., Watson, P., Page, D. L. et al.: Hereditary breast cancer: Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 77, 1996, s. 696-709.
38. Marks, J. R., Davidoff, A. M., Kerns, B. J. et al.: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer. Res., 51, 1991, s.2979-2989.
39. Meden, H., Marx, D., Roeglen, T. et al.: Overexpression of the oncogene e-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int. J. Gynecol. Pathol., 17, 1998, s. 61-65.
40. Nagele, F., Petru, E., Medl, M. et al.: Preoperative Ca 125; An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet. Gynecol., 86, 1995, s. 259-264.
41. Napier, M. P., Rustin, G. J. S.: Ca 125 as prognostic factor. CME, J. Gynec. Oncol., 4, 1999, s. 24-29.
42. Nguen, H. N., Averette, H. E., Hoskins, W. et al.: National survey of ovarian carcinoma VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer, 72, 1993, s. 3007-3011.
43. Nikrui, N.: Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol. Oncol., 12, 1981, s. 107-119.
44. Noguchi, T. et al.: Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J. Steroid. Biochem. Mol. Biol., 44, 1993, s. 657-660.
45. Obermair,A., Preyer, O., Leodolter, S.: Tumor angiogenesis and its relation to prognosis in epithelial ovarian cancer. CME, J. Gnyec. Oncol., 4, 1999, s. 169-177.
46. O'Brien, M. E. R., Schofield, J. B., Tan, S. et al.: Clear cell epithalial ovarian cancer (mesonephroid): Bad prognosis only in early stages. Gynecol., 49, 1993, s. 250-254.
47. Ozols, R. F., Rubin, S. C., Thomas, G. N. et al.: Epithalial ovarian cancer. In: Hoskins, W. J., Perez, C. A., Young, R. C.: Principles and Practice of Gynecologic Oncology. Lippicont Williams & Wilkins, 2000, s. 981-1057.
48. Regateiro, F. J.: Epithelial ovarian carcinoma and prognostic significance of c-erbB-2 (HER-2/neu), bcl-2, metastasis suppressor gene (nm23), and DNA mismatch repair genes. CME, J. Gynec. Oncol., 4, 1999, s. 219-225.
49. Rose, F. R. et al.: Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oneogene, 12, 1996, s. 999-1003.
50. Rubin, S. C., Benjamin, I., Behbakht, K. et al.: Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. N. Engl. J. Med., 335, 1996, s. 1413-1416.
51. Rubin, S. C., Finstad, C. L., Wong, G. Y. et al.: Prognostic significance of HER-2/neu expression in advanced ovarian cancer. Am. J. Obstet. Gynecol., 168, 1993, s. 162-169.
52. Sanna, E. et al.: Multivariate analysis of DNA ploidy, steroid hormone receptors and CA125, as prognostic factors in ovarian carcinoma: a prospective study. Nutrition, 5 (Suppl), 1995.
53. Serov, S. F., Scully, R. E., Sobin, L. H.: Histologic typing of ovarian tumours. In International Histological Classification of Tumours. No 9. Geneva, World Health Organization, 1973.
54. Sheridan, E., Silcocks, P., Smith, B. et al.: p53 mutation in a series of epithelial ovarian cancers from the UK and its prognostic significance. Eur. J. Cancer, 30A, 1994, s. 1701-1704.
55. Slamon, D. J., Godolphin, W., Jones, L. A. et al.: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science, 244-1989, s. 707-712.
56. Sorbe, B., Frankendal, B., Veress, B.: Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet. Gynecol., 59, 1982, s. 576-582.
57. Staunton, M. J., Gaffney, E. F.: Tumor type is a determinant of susceptibility to apoptosis. Am. J. Clin. Pathol., 103, 1995, s. 300-307.
58. Surwit, E., Childers, J., Atlas, I. et al.: Neoadjuvant chemotherapy for advanced ovarian cancer. Int. J. Gynecol. Cancer, 6, 1996, s. 356-361.
59. Swenerton, K. D., Hislop, T. G., Spinelli, J. et al.: Ovarian carcinoma: A multivariate analysis of progonstic factors. Obstet. Gynecol.k, 65, 1985, s. 264-269.
60. Tandon, A. K., Clark, G. M., Ghamness, G. L. et al.: Her-2/neu oncogene protein and prognosis inbreast cancer. J. Clin. Oncol., 7, 1989, s. 1120-1128.
61. Trapan, A. et al.: Estrogen receptors and progesterone receptors in ovarian cancer. Min. Gynecol., 44, 1992, s. 307-312.
62. Tropé, C., Kaern, J.: DNA ploidy in epithalial ovarian cancer: a new independent prognostic factor! CME, J. Gynec. Oncol., 4, 1999, s. 154-160.
63. Vergote, I., Kaern, J., Abeler, V. M. et al.: Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am. J. Obstet. Gnyecol., 169, 1993, s. 40-52.
64. Webb, P. M., Green, A., Cummings, M. C. et al.: Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J. Natl. Cancer Inst., 90, 1998, s. 1729-1734.
65. Young, R. C., Walton, L. A., Ellenberg, S. S. et al.: Adjuvant therapy in Stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med., 322, 1990, s. 1021-1027.
66. Zweemer, R. P., Berchuck, A., Jacobs, I. J.: Somatic genetic events in BRCA1 and BRCA2 - related ovarian cancer. CME, J. Gynec Oncol., 4, 1999, s. 112-115.